IAVI and CureVac partner to further AIDS vaccine candidates
The two organizations will use innovative immunogens, which were created by IAVI and its partners, to carry novel messenger RNA (mRNA) technology to the immune system.
"This collaboration could be a real game-changer," IAVI Chief Scientific Officer Wayne Koff said. "The development of vaccines that can generate neutralizing antibodies against HIV is a top priority for IAVI and many other researchers. Researchers at IAVI's Neutralizing Antibody Center at The Scripps Research Institute and elsewhere have designed several novel immunogens that have the potential to elicit such antibodies. We are very hopeful that using mRNA will enable us to develop and test these immunogens comparatively quickly, saving both time and money."
Because the envelope protein for HIV is the main target for antibodies that eliminate the strains, researchers have created immunogens that mimic the protein to aid the immune system in recognizing HIV and fighting against it in the future.
"IAVI is an ideal partner to bring highly innovative HIV vaccine designs into human testing," Ingmar Hoerr, CureVac co-founder and CEO, said. "We are excited to benefit from IAVI's expertise in AIDS vaccine development, and its network and experience across the United States, Europe, Africa and India and to accelerate such development on the basis of our RNActive technology."